Nektar Therapeutics Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-4.2%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$8.47next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Marketable Securities Balance Quarterly731.6MTarget: Maintain sufficient runway to fund Phase 3 trials through Q3 2028
Quarterly Non-Cash Royalty Revenue Quarterly10.9MTarget: 40000000 to 45000000 annually
Quarterly Research and Development (R&D) Expense Quarterly35.7MTarget: Manage clinical trial costs as Phase 3 ZENITH-AD program ramps up
Watch Items
- Initiation of ZENITH-AD Phase 3 program of rezpegaldesleukin in moderate-to-severe atopic dermatitisTrigger: Study initiation by July 2026Action: Monitor clinical trial registry updates and company press releases for first patient dosed
- End-of-Phase 2 Meeting with FDA for rezpegaldesleukin in alopecia areataTrigger: Meeting alignment in Q2 2026Action: Review regulatory feedback and finalization of Phase 3 trial design parameters
- 24-week off-treatment observation data from REZOLVE-AA trial in alopecia areataTrigger: Data readout in Q4 2026Action: Evaluate durability of response and safety profile during the off-treatment phase
Research as of 19 Jun 2026